by Rod Raynovich | May 26, 2011 | BIOgraph
Here is a brief review of stocks to watch with potential ASCO impact although it is likely that prices already reflect the scientific news: Ariad Pharmaceuticals Inc. (ARIA $8.43) up 0.36% will present Phase III data on ponatinab, its investigational pan-BCR-ABL and...